NCT03867084: Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

Sponsor: Merck Sharp & Dohme LLC. Phase: PHASE3. Conditions: Hepatocellular Carcinoma